In the second part of his conversation with HCPLive, Raffi Tachdjian, MD, MPH, from the department of pediatrics at the University of California Los Angeles, further contextualized new real-world data demonstrating sustained reductions in 

 attack rates at 18 months following initiation of berotralstat (ORLADEYO).

Tachdjian emphasized that one of the most clinically meaningful aspects of the analysis is its scale and inclusion of patients with normal C1 inhibitor HAE (HAE-nC1INH), a subgroup historically underrepresented in clinical trials. The study cohort represents one of the largest real-world populations receiving long-term oral prophylaxis, offering insight into treatment performance beyond controlled trial settings.

The analysis included patients with HAE from Optimal Care (Dec 2020–Jan 2024) with ≥ 2 dispensings and documented attack assessments before and after treatment. Among the sample, 390 had a C1 esterase inhibitor (C1INH) deficiency, and 311 had normal C1INH (HAE-nC1INH).

Over 12 months, mean monthly attack rates decreased from 2.50 to 0.79 among patients with HAE-C1INH and from 4.59 to 1.68 among those with HAE-nC1INH (both P <.001). Reductions continued through 18 months of follow-up and were observed regardless of baseline attack frequency or HAE subtype.

In this Q&A, Tachdjian explains how to interpret the sustained attack reductions at 12 and 18 months, explores differences in response between HAE-C1INH and HAE-nC1INH that may influence treatment decisions, and discusses how these real-world data complement or differ from findings in clinical trials.

 What is the most clinically meaningful takeaway from these real-world attack rate reductions following berotralstat initiation?

The exciting thing about this study is that it represents one of the largest real-world patient population cohorts that are receiving long-term prophylaxis for hereditary angioedema, and this [includes] patients with normal C1 inhibitor HAE. This is a population in which clinical data are limited.

 How should clinicians interpret the sustained reductions at 12 and 18 months when counseling patients about long-term prophylaxis expectations?

The significant attack reductions observed at 12 months and sustained at 18 months in this study suggest that the clinical benefit of treatment with ORLADEYO can be maintained over time, including in patients with higher baseline disease activity and different HAE types. This provides additional context for treatment discussions, reinforcing that long-term prophylaxis with ORLADEYO can offer durable disease control for many patients—an essential objective in the management of hereditary angioedema.

 Were there differences in response between HAE-C1INH and HAE-nC1INH that should influence treatment strategy?

In this real-world study, we observed clinically and statistically meaningful differences in response for patients with HAE-C1INH and those with HAE-nC1INH, which is notable given the more limited evidence base in the latter group. These findings suggest that ORLADEYO could be considered as part of a long-term prophylactic strategy for people with HAE regardless of type.

 How does real-world specialty pharmacy data complement—or differ from—what we learned in clinical trials?

While clinical trials establish efficacy and safety in a controlled environment, real-world specialty pharmacy data show us how ORLADEYO performs across a diverse HAE population in routine clinical practice, including patients with varying disease severity and types. Seeing significant and sustained attack reductions outside the trial setting through a protocol-driven real-world study reinforces confidence in the role of ORLADEYO as a long-term prophylactic option across HAE types and disease severity.

Tachdjian R. HCPLive. Sustained HAE Attack Reductions at 18 Months with Berotralstat, With Raffi Tachdjian, MD. HCPLive. Published on February 16, 2026. Accessed on February 18, 2026. 

https://www.hcplive.com/view/sustained-hae-attack-reductions-18-months-berotralstat-raffi-tachdjian-md

Davis-Lorton M, Tachdjian R, Lopez-Gonzalez L, et al. Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world. 

Articles

A large specialty pharmacy cohort supports sustained reductions in attack rates across HAE subtypes, including normal C1 inhibitor disease.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Real-World HAE Control with Berotralstat at 18 Months, With Raffi Tachdjian, MD

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

 in children and adolescents recommends sebetralstat, an oral plasma kallikrein inhibitor, as a first-line option for the acute treatment of attacks in patients aged ≥ 12 years. The guidance places particular emphasis on early treatment, self-administration, and ensuring on-demand therapy is accessible “anytime, anywhere.”

For clinicians managing pediatric HAE, the update formalizes a shift that has been evolving over the past decade: from reactive, injection-based rescue treatment toward rapid, patient-controlled intervention at the earliest sign of symptoms. The committee issued a strong recommendation for sebetralstat in adolescents, based on clinical trial evidence and recent regulatory approvals.

Recommend oral sebetralstat as first-line on-demand therapy for adolescents aged ≥12 years

Ensure all pediatric patients have on-demand therapy available at all times

Treat attacks as early as possible at symptom onset

Consider treatment for all attacks, regardless of anatomic location or perceived severity

Maintain supply sufficient to treat ≥ 2 attacks, even in patients receiving long-term prophylaxis

Sebetralstat (Ekterly) is a small-molecule, oral plasma kallikrein inhibitor designed for on-demand treatment of acute HAE attacks. Its US Food & Drug Administration (FDA) approval in July 2025 for patients aged ≥12 years was supported by the phase 3 KONFIDENT trial, which demonstrated significantly faster time to beginning of symptom relief compared with placebo.

 The drug has also received marketing authorization in the European Union and other regions.

“The first-line recommendation for EKTERLY so soon after becoming commercially available underscores the strength of our clinical data and reinforces the importance of ensuring patients have immediate access to effective on-demand therapy,” said Paul Audhya, MD, MBA, chief medical officer of KalVista.

 “As the first and only oral on-demand treatment for HAE, EKTERLY uniquely enables guideline-aligned care by supporting early intervention and simplifying self-administration.”

Pooled data from KONFIDENT and KONFIDENT-S demonstrated that the mean time to achieve symptom relief was less than 2 hours (1.79; range, 0.76 – 7.12).

 On average, reduction in severity took 3.58 hours, and complete attack resolution took 15.09 hours.

The new pediatric guideline incorporates these data into broader management recommendations. The panel advises that all pediatric patients with HAE should have immediate access to on-demand therapy, treat attacks as early as possible, and consider treating all attacks regardless of location or severity.

Patients should maintain an adequate supply to treat ≥ 2 attacks, even if receiving long-term prophylaxis. The guideline also recommends ensuring on-demand treatment is available during medical, dental, or surgical procedures and emphasizes maintaining normal activities when rapid treatment access is secured.

These recommendations build on prior international consensus guidance, including the 2022 WAO/EAACI HAE guideline, which also stressed early treatment and universal access to on-demand therapy.

 What distinguishes the pediatric update is its explicit framing around developmental and psychosocial considerations, including the burden of injections in adolescents and the importance of self-efficacy in disease management.

Before the availability of oral on-demand therapy, acute HAE treatment options included intravenous or subcutaneous plasma-derived C1-INH, recombinant C1-INH, the bradykinin B2 receptor antagonist icatibant, and the kallikrein inhibitor ecallantide.

 Although effective, these agents require injection or infusion, which may contribute to delays in treatment, particularly in younger patients dependent on caregivers.

Although the guideline strongly recommends sebetralstat in adolescents aged ≥ 12 years, several caveats remain. Head-to-head comparative data between sebetralstat and injectable therapies are lacking. Real-world effectiveness and adherence data in pediatric populations are still emerging.

Younger children remain an unmet need. The ongoing KONFIDENT-KID study is evaluating sebetralstat in children aged 2 to 11 years, with safety and pharmacokinetic data anticipated to inform future regulatory submissions.

At present, sebetralstat is not approved for patients younger than 12 years.

The guideline signals a maturation of pediatric HAE care, integrating pathophysiologic rationale, trial evidence, and patient-centered considerations.

 For clinicians, the key message is less about replacing existing therapies and more about ensuring rapid, reliable access to early treatment in a population for whom timing and feasibility are critical determinants of outcome.

“Ped-HAE-C1INHs deserve special attention in the diagnosis and management of their disease,” wrote first author Henriette Farkas, from Semmelweis University, in Hungary, and colleagues.

 “Early diagnosis, family screening, education and counseling of patients and their caregivers, selection of appropriate individualized therapy, development of a therapeutic strategic plan with shared decision making, centralized care, and regular follow-up of patients are essential to reach the goal of ensuring that these young patients can lead normal lives similar to their peers.”

KalVista Pharmaceuticals Announces Inclusion of EKTERLY® (sebetralstat) as a First-Line Therapy for Adolescents 12 and Older in International Pediatric HAE Guideline. BusinessWire. Published on February 18, 2026. Accessed on February 18, 2026. 

https://www.businesswire.com/news/home/20260218359223/en/KalVista-Pharmaceuticals-Announces-Inclusion-of-EKTERLY-sebetralstat-as-a-First-Line-Therapy-for-Adolescents-12-and-Older-in-International-Pediatric-HAE-Guideline

Farkas H, Martinez-Saguer I, Bork K, et al. International guideline on the diagnosis and management of pediatric patients with hereditary angioedema. 

Johnson V. HCPLive. Sebetralstat FDA-Approved as First Oral, On-Demand for Hereditary Angioedema. Published on July 7, 2025. Accessed on February 18, 2026. 

https://www.hcplive.com/view/sebetralstat-fda-approved-as-first-oral-on-demand-for-hereditary-angioedema

KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema. Kalvista. Published on September 19, 2025. Accessed on February 18, 2026. 

https://kalvista.gcs-web.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-european-commission-and

Maurer M, Magerl M, Betschel S, et al. The international WAO/EAACI guideline for the management of hereditary angioedema-The 2021 revision and update. 

Approved HAE Treatments. US Hereditary Angioedema Association. Accessed on February 18, 2026. 

Updated international guidance reinforces early self-administered on-demand therapy and integrates newer kallikrein-targeted agents into routine HAE management.


Pediatric HAE Guideline Recommends Sebetralstat as First-Line Therapy

Alan Buchman MD, MSPH, is a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health.

Accurately defining the population of patients with short bowel syndrome (SBS) and intestinal failure has long been a challenge in gastroenterology.

In an effort to bring greater clarity to the field, Alan Buchman MD, MSPH, a professor of Clinical Surgery and Medical Director of the Intestinal Rehabilitation and Transplant Center at the University of Illinois at Chicago and director of gastroenterology at Elevance Health, led the introduction of new, more specific ICD-10-CM codes for SBS, along with corresponding updates to World Health Organization ICD-11 classifications. His recent real-world US claims analysis presented at the ASPEN 2026 Nutrition Science and Practice Conference examined how widely those codes have been adopted and what that adoption, or lack thereof, reveals about disease burden and clinical practice.

A a condition that develops when the small intestine is shortened or damaged and cannot absorb enough nutrients from the foods you eat to maintain health, Buchman says that historically, estimates of SBS prevalence have varied widely, in part because clinicians relied on nonspecific codes such as “postoperative malabsorption,” a designation that could encompass a broad spectrum of patients, from those with minimal ileal resections and vitamin B12 deficiency to individuals with near-total small bowel loss and true intestinal failure. The lack of granularity made it nearly impossible to determine the true size and characteristics of the SBS population, including distinctions between patients with end ileostomies and those with colon in continuity, groups with differing management strategies and prognoses.

After allowing a year for uptake of the new codes, Buchman and colleagues analyzed claims data using proxy estimates derived from 29 parenteral nutrition–related codes, as well as prior malabsorption codes. They found that only about 28% of the expected patient population was identified using the new SBS-specific codes.

“What this tells us is one of two things: either the population is much smaller than what we had originally envisioned, or people are not using the new codes appropriately,” Buchman said.

He says his experience in both clinical practice and the insurance sector suggests that both undercoding and miscoding are occurring. Some patients without SBS are being assigned the new codes, while others who clearly meet criteria are not. He attributes this variability to several factors, including knowledge gaps, inconsistent documentation, and the heavy burden placed on coders who must navigate thousands of evolving codes each year.

“There's a variety of communication errors and miscommunications that probably occur, but the coding is extremely important because the only way that we can identify over a population how these patients do is to target the populations, and we've got to be able to identify the patients correctly,” he explained

Buchman notes that improved coding accuracy is not just an administrative issue. Precise identification of patients is essential for appropriate treatment selection, including use of therapies such as teduglutide (Gattex), as well as for research, clinical trial enrollment, and population-level outcomes tracking.

As code adoption improves through targeted education of both clinicians and coding professionals, the field may finally gain a clearer understanding of SBS prevalence, disease progression, and long-term outcomes.

NIDDK. Short Bowel Syndrome. April 2023. Accessed February 18, 2026. 

https://www.niddk.nih.gov/health-information/digestive-diseases/short-bowel-syndrome

Kochar B, Herfarth HH. Teduglutide for the treatment of short bowel syndrome - a safety evaluation. 

. 2018;17(7):733-739. doi:10.1080/14740338.2018.1483332

Videos

New data show limited uptake of SBS-specific ICD-10 codes, raising concerns about misclassification and the true burden of disease.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

ICD-10 Adoption and the True Burden of Short Bowel Syndrome, With Alan Buchman, MD, MSPH

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Deepak Bhatt, MD | Image Credit: Mount Sinai

On February 18, 2026, GSK announced new efficacy data for 

 Vaccine, Adjuvanted (AREXVY), noting an observed reaction in 

 and RSV-related hospitalizations in adults ≥60 years.

Although RSV is primarily known for its high disease burden among infants and pediatric patients, it is increasingly recognized as the central cause for a substantial amount of respiratory illness in older adults. Despite being largely mild to moderate, RSV can result in hospitalization, serious complications such as heart attack, 

chronic obstructive pulmonary disease (COPD)

AREXVY is composed of recombinant RSV glycoprotein F, stabilized in the prefusion conformation, combined with GSK’s proprietary adjuvant AS01E. The vaccine is currently indicated for the prevention of lower respiratory tract disease (LRTD) due to RSV in patients aged ≥60 years and for those ages 50-59 who are at an increased risk for LRTD caused by RSV.

“In the real-world data being presented at RSVVW’26, it is observed that RSV vaccination could help reduce the risk of certain serious RSV-related outcomes, potentially including major adverse cardiovascular events such as heart attack and stroke, as well as severe flare-ups of COPD and asthma,” Deepak Bhatt, MD, MPH, director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, said in a statement. “These new data are a significant step in our understanding of how to help prevent such RSV-related health outcomes. I look forward to more data investigating this association further.”

This retrospective cohort study, conducted across the US, included >2.5 million patients, of whom 520,440 were vaccinated. These patients were exact matched in a 1:4 ratio to 2,081,760 patients who did not receive the vaccine. The vaccinated group received treatment between August 2023 and May 2024.

During the study, the vaccine was associated with 75.6% effectiveness against RSV-related hospitalization at a median follow-up period of 5.6 months post-vaccination (unvaccinated group, n = 1419/2,081,760; vaccinated group, n = 95/520,440; 95% CI, 69.8-80.2%). Additional exploratory endpoints indicated 63.1% vaccine effectiveness against major adverse cardiovascular events, including heart attack and stroke, during hospitalization among patients aged ≥60 years (unvaccinated, n = 212/699,177; vaccinated, n = 21/170,803; 95% CI, 41.8-76.6%).

The vaccine also showed 74.4% and 61.6% effectiveness against severe COPD and asthma flare-ups, respectively (COPD unvaccinated, n = 265/286,406; vaccinated, n = 20/76,209; 95% CI, 59.3-83.9%. Asthma unvaccinated, n = 57/190,590; vaccinated, n = 7/53,636; 95% CI, 9.1-83.7%).

Another nationwide cohort study was conducted in Denmark among patients with COPD aged ≥60 years. During this study, the vaccine displayed an effectiveness of 100% in preventing RSV-related hospitalizations (unvaccinated, n = 115/89,376; vaccinated, n = 0/7448; 95% CI, 71.1-100%).

“These data underscore the value of our RSV vaccine in its observed association with helping to prevent RSV-related hospitalization and reducing the risk of acute events of certain chronic conditions associated with this potentially serious disease,” Christian Felter, GSK Global Medical Lead, RSV, said in a statement. “We are proud of our contribution at the forefront of generating innovative research in RSV to inform the clinical community and improve outcomes for patients.”

Full data from both the US and Denmark studies will be presented at RSVVW’26, the 9th Conference of the Respiratory Syncytial Virus Foundation (ReSViNET) in Rome, Italy, from February 17-20.

GSK. GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke, and Severe Flare-Ups of COPD and Asthma, Real World Study Shows. 

. February 18, 2026. Accessed February 18, 2026. 

https://www.businesswire.com/news/home/20260217706893/en/GSKs-AREXVY-Associated-With-Reductions-in-Certain-RSV-Related-Risks-Including-Heart-Attack-Stroke-and-Severe-Flare-Ups-of-COPD-and-Asthma-Real-World-Study-Shows

Savic M, Penders Y, Shi T, Branche A, Pirçon J. Respiratory syncytial virus disease burden in adults aged 60 years and older in high‐income countries: A systematic literature review and meta‐analysis. Influenza and Other Respiratory Viruses. 2022;17(1). 

These retrospective cohort studies also showed the vaccine’s reduction of heart attack, stroke, and asthma/COPD flare-ups in patients with RSV.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Asthma

The HCPLive asthma page is a comprehensive resource for clinical news and insights on asthmatic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for allergic and severe asthma, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSV

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

 and obesity or overweight, combined ixekizumab (Taltz) and tirzepatide (Zepbound) treatment delivers significantly greater improvements in both skin clearance and weight reduction versus ixekizumab alone.

This new release by Eli Lilly and Company on February 18 pointed to positive topline findings from the phase 3b TOGETHER-PsO trial, an open-label analysis evaluating the combined use of ixekizumab and tirzepatide versus ixekizumab alone. The data were seen as significant, as in the US, roughly 61% of those with psoriasis are impacted by obesity or overweight, accompanied by at least a single related comorbidity.

"Psoriasis and obesity share underlying inflammatory pathways, yet they are too often treated in silos despite psoriasis treatment guidelines calling for obesity management," Mark Lebwohl, MD, dean for Clinical Therapeutics, professor and Chairman Emeritus of the Department of Dermatology at the Icahn School of Medicine at Mount Sinai, and TOGETHER-PsO principal investigator, said in a statement.

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist indicated for those in need of chronic weight management. The medication promotes weight loss by diminishing one’s appetite and caloric intake and is 

 approved for use alongside a reduced-calorie diet and increased physical activity in adults with obesity, or in those who are overweight with at least a single weight-related comorbidity.

Ixekizumab is a monoclonal antibody designed to target interleukin (IL)-17A, blocking its interaction with the IL-17 receptor to diminish the inflammatory signaling seen in psoriasis. Building on prior positive data from the TOGETHER-PsA study, this medication is currently the only biologic supported by clinical research assessing its implementation in combination with an incretin-based therapy for those with psoriasis or psoriatic arthritis (PsA) who also have obesity or overweight.

In the TOGETHER-PsO study (NCT06588283), a 52-week, randomized, multicenter, assessor-blinded, open-label phase 3b analysis, investigators involved a total of 274 adults. These patients were randomized 1:1 to receive subcutaneous ixekizumab either alone or in combination with tirzepatide. All of those recruited were given guidance on calorie restriction and physical activity.

A body mass index (BMI) of at least 30 kg/m², or 27 to less than 30 kg/m² was required for eligibility, along with at least 1 weight-related comorbidity. The study’s main endpoint looked at the proportion of participants achieving complete skin clearance. The latter would be defined as Psoriasis Area and Severity Index (PASI) 100, together with at least 10% weight loss at the 36-week mark.

By the 36-week mark, the investigative team found 27.1% of patients on combination therapy were successful in attaining both PASI 100 and a minimum 10% reduction in weight.

 This was compared with only 5.8% of those treated with ixekizumab alone (

 < .001), meeting the study’s primary endpoint. In a key secondary analysis, the team noted 40.6% of subjects in the combination cohort attained PASI 100 versus 29.0% in the monotherapy cohort, reflecting a 40% relative increase (

Adverse events (AEs) with combination therapy were generally shown to be mild to moderate.

 They also aligned with the known safety profiles of each of these medications. AEs were observed in at least 5% of participants on both therapies included diarrhea, nausea, constipation, injection site reactions, vomiting, dosing errors, and dizziness. In the ixekizumab-only arm, the most frequent AEs were shown to be errors in dosing, injection site reactions, and nasopharyngitis.

In this release, Lilly noted the 36-week findings are expected to be published in a peer-reviewed journal and shared with regulatory authorities.

"This study involved patients with particularly high BMI and difficult-to-treat psoriasis, making the PASI 100 results with Taltz plus Zepbound especially remarkable,” Lebwohl said in his statement.

 “The findings show that treating psoriasis and obesity or overweight at the same time significantly improved outcomes, reinforcing psoriasis as an obesity-related condition and supporting a potential comprehensive approach to care."

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight. Eli Lilly. February 18, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-0

Armstrong et al, Addressing the Obesity-Psoriasis Connection: Prevalence, Incidence, and Comorbidity Insights from a Large US Population of 19.9 Million (2018-2024). Presented at Maui Derm, 2026.

These data, released by Lilly, suggest ixekizumab (Taltz) and tirzepatide (Zepbound) are more effective when used together versus ixekizumab monotherapy.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight

Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

Navar discusses the positive data from the phase 3 trial and emphasizes substantial treatment adherence throughout the 52-week period.

Dyslipidemia

CORALreef Lipids: Enlicitide Reduces LDL-C in Patients With ASCVD, With Ann Marie Navar, MD, PhD

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Dermatology leaders preview 2026 breakthroughs including oral psoriasis drugs, new biologics, novel acne drugs, and AI tools transforming patient care.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

What’s Next in Dermatology? Dermatologists Weigh In On 2026

Sophie Stocker is an Associate Professor in the Sydney Pharmacy School. She is also an Honorary Senior Hospital Scientist in the Department of Clinical Pharmacology and Toxicology at St Vincent's Hospital, Sydney; an Adjunct Senior Lecturer of the St Vincent's Clinical School, University of New South Wales; and an Honorary Scientist at the Garvan Medical Research Institute.

Stocker discusses the potential for a wearable patch to continuous drug measurement of vancomycin, especially in pediatric patients and outpatient settings.



Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Wearable Patch May Prevent Acute Kidney Injury

Abraham Kazemi, MD, is the director of Cosmetic and Laser Dermatology for Virginia’s Pinnacle Dermatology sites.

This clip from the latest episode of the Skin of Color Savvy podcast highlights Kazemi's experiences as a dermatologist working to help underserved communities.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Hosted by Skin of Color Society and produced by HCPLive, 

 delves into the latest research, clinical insights, and culturally intelligent care practices in dermatology with leading experts. 

Whether it’s groundbreaking research, practice-changing insights, or highlights from the SOCS community, this twice-monthly program provides dermatologists and care providers with expert perspectives on treating patients with skin of color.

Daily Challenges as a Dermatologist Helping Underserved Patients

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Diabetes Dialogue Cohosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, cover the patient awareness motivation behind Novo Nordisk’s recent announcement.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Strategic Alliance Partnership

Novo Nordisk Rebrands Rybelsus as Ozempic to Increase Patient Awareness

In this segment, Dr Cristancho describes a pragmatic follow-up schedule and objective criteria—including early weight-loss benchmarks—to determine whether to continue, adjust, or discontinue non-incretin treatment.

Follow-up structure and objective thresholds for evaluating non-incretin therapy

Dr Cristancho reviews the targeted role of sympathomimetic agents and outlines essential cardiovascular, psychiatric, and drug–drug interaction assessments before initiating non-incretin medications.

Sympathomimetic agents and baseline safety assessment in obesity pharmacotherapy

David Rizik, MD, is an interventional cardiologist at Banner University Health.

Rizik and Morris discuss the Heartflow PCI Navigator and its promising implications for patients – and how they manage that excitement while waiting for trial data.

Balancing Enthusiasm for New Technologies With the Need for Trial Data, With David Rizik, MD, and Michael Morris, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Experts in nephrology explain the benefits of kidney transplantation, the evolving immunosuppression landscape, and evaluate the risk factors for donors. 


Chronic Kidney Disease

Breaking Down The Kidney Transplant Landscape on National Donor Day

Walter J. Liszewski, MD, is an associate professor of dermatology and cancer epidemiology at Northwestern University Feinberg School of Medicine.

This Q&A summarizes a recent 2026 Maui Derm Hawaii interview with Walter J. Liszewski, MD, regarding contact dermatitis updates.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Latest News

Real-World HAE Control with Berotralstat at 18 Months, With Raffi Tachdjian, MD

Pediatric HAE Guideline Recommends Sebetralstat as First-Line Therapy

ICD-10 Adoption and the True Burden of Short Bowel Syndrome, With Alan Buchman, MD, MSPH

AREXVY Vaccine Reduces Hospitalization, Major Adverse Cardiovascular Events in RSV

Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight